Recent Updates
Recently added Catalysts

Niagen, Niagen, Niagen

Phase 1

Pharmacokinetics | Unknown | Other |Niagen Bioscience, Inc.|Trials Updated: Sep 9, 2014

Success Probability

Subscribe to view

Market & Valuation

Subscribe to view

Trial Design

RandomizedDouble-BlindCONTROLLED
Total Trials1
Total Enrollment12

FDA Designations

ORPHAN_DRUGPRIORITY_REVIEW

Niagen, Niagen, Niagen clinical trials

Niagen, Niagen, Niagen · 1 trial · 1 indication

Phase 1 1
NCT02191462A Study of the Pharmacokinetics of Three Dosages of Niagen in Healthy SubjectsPharmacokinetics
COMPLETED12 Analytics
PHASE1COMPLETED
A Study of the Pharmacokinetics of Three Dosages of Niagen in Healthy Subjects
PharmacokineticsUnlock trial analytics

Study Endpoints

Primary Endpoints

t1/2 (terminal half-life)
24 hours

24 hour dosing period; 3 dosing periods each separated by 7 day washout

Unlock Study Endpoints

Study Design & Arms

AllocationRANDOMIZED
MaskingTRIPLE
ModelCROSSOVER

Treatment Arms

ArmTypeDescription
Niagen 100mgEXPERIMENTAL1 Niagen capsule (1 x 100 mg capsule) and 9 Placebo capsules
Niagen 300mgEXPERIMENTAL3 Niagen capsules (3 x 100mg capsule) and 7 Placebo capsules
1000mg NiagenEXPERIMENTAL10 Niagen capsules (10 x 100mg capsule)

Interventions

NameTypeDescription
Niagen 100mgDIETARY_SUPPLEMENT -
Niagen 300mgDIETARY_SUPPLEMENT -
Niagen 1000mgDIETARY_SUPPLEMENT -
Unlock Study Design Details

Eligibility Criteria

Age Range30 Years to 55 Years
SexALL
Healthy VolunteersYes
Study Sites1

Inclusion Criteria: * Healthy Male or female age 30-55 years * BMI 18.5-29.9 kg/m2 * If female, subject is not of child bearing potential, OR Females of childbearing potential must agree to use a medically approved method of birth control and have a negative urine pregnancy test result. * Healthy a...

Countries:Canada
Unlock Eligibility Criteria